PTPRT and non-small cell lung carcinoma: PTPRT mutations improved survival and enhanced immunotherapy response in NSCLC and SKCM patients, which suggests that PTPRT may serve as a pan-cancer biomarker for immune checkpoint inhibitor efficacy.